Results 181 to 190 of about 78,686 (205)

Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma

Nature Reviews Clinical Oncology, 2013
Jane L Messina, Vernon K Sondak, Keiran S M Smalley   +2 more
exaly  

An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling

Cancer Cell, 2016
Zoi Karoulia, Qisheng Xin, Xuewei Wu
exaly  

Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance

Cancer Cell, 2016
Michaël Cerezo, Thomas Botton, Cyril Ronco   +2 more
exaly  

BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval

Nature Reviews Drug Discovery, 2022
exaly  

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

New England Journal of Medicine, 2014
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas   +2 more
exaly  

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

New England Journal of Medicine, 2011
Paul B Chapman, Caroline Robert, James Larkin   +2 more
exaly  

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

Cancer Cell, 2010
Jessie Villanueva, Adina Vultur, Damien Kee   +2 more
exaly  

Clinical Development of BRAF plus MEK Inhibitor Combinations

Trends in Cancer, 2020
Vivek Subbiah, John M Kirkwood
exaly  

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

New England Journal of Medicine, 2012
Keith T Flaherty, Adil I Daud, Jonathan Cebon   +2 more
exaly  

BRAF/MEK inhibitors

Reactions Weekly
openaire   +1 more source